Results 221 to 230 of about 3,775,993 (302)

Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk.

JAMA Netw Open
Sendaydiego X, Gold LS, Dubreuil M, Andrews JS, Reid P, Liew DFL, Goulabchand R, Singh AG, Hughes GC, Pioro M, Sparks JA, Jarvik JG, Singh S, Liew JW, Singh N.   +14 more
europepmc   +1 more source

Trends in the use of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and recently diagnosed colorectal, lung, or prostate cancer. [PDF]

Clin Rheumatol
Suarez-Almazor ME, Ruiz JI, Lei X, Wu CF, Zhao H, Rajan SS, Giordano SH.   +6 more
europepmc   +1 more source

Effect of Comedication With Conventional Synthetic Disease‐Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study

, 2016
Alexandre Sepriano, Sofía Ramiro, Désirée van der Heijde, Pedro Ávila-Ribeiro, R. Fonseca, J. Borges, L. Teixeira, P. Carvalho, Marcos Cerqueira, Joana Sousa‐Neves, T. Meirinhos, Anabela Barcelos, Graça Sequeira, Maria João Salvador, J. Canas da Silva, Helena Santos, Miguel Bernardes, Elsa Vieira‐Sousa, Helena Canhão, Jaime Branco, Fernando Pimentel‐Santos, Robert Landewé   +21 more
openalex   +1 more source

Influencers of Achievement of Remission and Low Disease Activity in Response to Disease-Modifying Antirheumatic Drugs (DMARDs) in Patients With Rheumatoid Arthritis. [PDF]

Cureus
Oyoo GO, Guantai A, Moots RJ, Okalebo F, Osanjo GO.   +4 more
europepmc   +1 more source

N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs

, 2016
I. G. Kirillova, Д. С. Новикова, Т. В. Попкова, Е Н Александрова, А. А. Новиков, Yu. N. Gorbunova, E. I. Markelova, Yu. O. Korsakova, С. И. Глухова, А. В. Волков, Е. Л. Лучихина, Н. В. Демидова, К. А. Касумова, С А Владимиров, M. A. Kanonirova, GV Lukina, Д. Е. Каратеев, E L Nasonov   +17 more
openalex   +1 more source

Toxicities Associated with Continuing Disease-Modifying Antirheumatic Drugs for Collagen Vascular Diseases During Head and Neck Intensity-Modulated Radiotherapy: A Single-Institution Experience. [PDF]

J Otolaryngol Head Neck Surg
Ni L, Phuong C, Yom SS, Chan JW.
europepmc   +1 more source

Major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a nationwide, population-based cohort study. [PDF]

Ther Adv Musculoskelet Dis
Kao CM, Chen YJ, Chen YM, Chen DY, Chen HH.   +4 more
europepmc   +1 more source

Comparative Effectiveness and Safety of the JAK Inhibitors and Biologic Disease-Modifying Antirheumatic Drugs in Treating Children With Nonsystemic Juvenile Idiopathic Arthritis: A Bayesian Meta-Analysis of Randomized Controlled Trials. [PDF]

ACR Open Rheumatol
Li Y, Huang B, Andorf S, Yue X, Lovell DJ, Brunner HI.   +5 more
europepmc   +1 more source

Effectiveness of JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort Study. [PDF]

Arthritis Rheumatol
Eberhard A, Di Giuseppe D, Askling J, Bergman S, Bower H, Chatzidionysiou K, Forsblad-d'Elia H, Kastbom A, Olofsson T, Frisell T, Turesson C.   +10 more
europepmc   +1 more source